Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
Become a Member | Sign in
Home>News>This Article

PGXL and Silicon Biosystems Collaborate

Published: Friday, April 26, 2013
Last Updated: Friday, April 26, 2013
Bookmark and Share
Companies to offer clinical research services focused on oncology genomics.

PGXL Technologies and Silicon Biosystems, Inc. announced a collaborative partnership to make the highly regarded Silicon Biosystems DEPArray technology available through PGXL Technologies. The PGXL program will allow clinical researchers and pharma sponsors to obtain the level of data fidelity and resolution needed in cancer biomarker discovery and translational research.

“As the DEPArray technology has gained recognition in the marketplace for its unmatched ability to recover pure cells for molecular characterization, we have received significant interest in having the platform available on a fee-for-service basis,” said Bob Proulx, President and General Manager of Silicon Biosystems’ U.S. operations. “Last year we added a demonstration and training lab, but partnering with PGXL for CRO services will add a whole new dimension to our ability to reach and impact the market.”

The DEPArray technology has broad application in the study of the underlying causes of disease, disease progression and the basis of drug resistance and efficacy. Recent technology progress in the areas of DNA and RNA analysis have shown that the complexity of diseases, like cancer, will require the characterization and comparison of different types of samples at the single cell level. The DEPArray system provides single-cell sorting, and can deliver the cell purity needed for the stringent downstream applications, such as next-gen sequencing and RNA expression profiling.

“We partnered with PGXL because they bring highly complementary capabilities and expertise to the equation,” Proulx continued. “Their experience in molecular methods and operation of a CLIA laboratory make them an ideal service provider for our prospective clients interested in genomic heterogeneity and translational research.”

“PGXL Tech exists to bring to market technologies that advance personalized medicine,” said Dr. Roland Valdes, Jr., President of PGXL Laboratories. “Making the DEPArray available on a fee-for-service basis empowers researchers to work with a precision that will speed discovery.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Cell's Waste Disposal System Regulates Body Clock Proteins
New way to identify interacting proteins could identify potential drug targets.
Compound Doubles Up On Cancer Detection
Researchers have found that tagging a pair of markers found almost exclusively on a common brain cancer yields a cancer signal that is both more obvious and more specific to cancer.
Promising Drug Candidate to Treat Chronic Itch
In a new study, scientists from the Florida campus of The Scripps Research Institute (TSRI) describe a class of compounds with the potential to stop chronic itch without the adverse side effects normally associated with medicating the condition.
Are Changes to Current Colorectal Cancer Screening Guidelines Required?
Editorial suggests more research is needed to pinpoint age to end aggressive screening.
Assessing Cancer Patient Survival and Drug Sensitivity
RNA editing events another way to investigate biomarkers and therapy targets.
New Molecular Marker for Killer Cells
Cell marker enables prognosis about the course of infections.
Potential Target for Treatment of Autism
Grant of $2.4 million will support further research.
Sniffing Out Cancer
Scientists have been exploring new ways to “smell” signs of cancer by analyzing what’s in patients’ breath.
Inroads Against Leukaemia
Potential for halting disease in molecule isolated from sea sponges.
Molecular ‘Kiss Of Death’ Flags Pathogens For Destruction
Researchers have discovered that our bodies mark pathogen-containing vacuoles for destruction by using a molecule called ubiquitin, commonly known as the "kiss of death."

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos